tbuckley/cabot-search huggingface dataset:
A randomized multicenter phase Ib/II study to assess the safety and the immunological effect of chemoradiation therapy (CRT) in combination with pembrolizumab (anti-PD1) to CRT alone in patients with resectable or borderline resectable pancreatic cancer.
Authors: Matthew H. G. Katz, Todd W. Bauer, Gauri R. Varadhachary, Gina R. Petroni, Timothy Bullock, Craig L. Slingluff, Osama E. Rahma
Journal: Journal of Clinical Oncology (2015)

TPS3098 Background: Tumor-infiltrating lymphocytes (TILs) play a major role in anti-tumor immune responses, and their presence is correlated with survival in a variety of tumors. These TILs do not reach the pancreatic cancer (PC) cells in significant numbers due to the presence of stroma and a suppressive microenvironment. One of the leading causes for immune suppression is elevated expression of PD-L1 either by the tumor cells or the surrounding regulatory cells, resulting in dysfunction of TILs. There is recent evidence to suggest that CRT can increase the presence of TILs in the PC microenvironment (PCME), leading to production of interferon-γ (IFN-γ), which could increase the expression of PD-L1 through a negative feedback loop. Methods: This is a prospective multicenter randomized trial that will accrue subjects with resectable or borderline resectable PC who had not received prior treatment. The primary objectives of the study are: (1) to determine the safety of neoadjuvant CRT in combination with pembrolizumab. (2) To estimate the difference in the number of TILs in PC subjects receiving neoadjuvant CRT in combination with pembrolizumab to the number of TILs in subjects receiving neoadjuvant CRT alone. This study will also investigate the effect of CRT+/- anti-PD-1 on the other effector and suppressive immune cells. Eligible subjects will be randomized 2:1 to the investigational treatment (Arm A) to receive pembrolizumab administered IV every 3 weeks on days 1, 22, and 43 during concurrent CRT with capecitabine (825 mg/m2 orally twice daily on days of radiation only) and radiation (50.4 Gy in 28 fractions over 28 days) or Arm B to receive only concurrent CRT with capecitabine. Patients without local or distant disease progression will be taken to the operative room for planned surgery (within 2 weeks of imaging). Postoperatively, resected patients will receive off study standard of care adjuvant gemcitabine (1000mg/kg IV weekly for 3 out of 4 weeks for 6 months). Post operatively resected patients will be followed for up for PFS and OS for up to 2 years. Clinical trial information: NCT02305186.
GW27-e1255 Improvement of long term risks of cardiovascular events associated with community based disease management in chinese patients of the xin jiang autonomous region of china
Authors: Yang Li, Cai Minzhang, Ma Minghui, Huang Xinmiao, Liu Laixin, Wang Bei, Zhu Minglei, Zhu Weihai, Zhe Wei, Guan Yumei, Thitima Kongnakorn, Siyang Peng, Thomas Hach
Journal: Journal of the American College of Cardiology (2016)
TCT-314 Impact of Longitudinal Lesion Geometry on Location of Plaque Rupture and Clinical Presentations
Authors: Joo Myung Lee, Gilwoo Choi, Doyeon Hwang, Jonghanne Park, Hyun Jin Kim, Joon-Hyung Doh, Chang-Wook Nam, Sang-Hoon Na, Eun-Seok Shin, Charles A. Taylor, Bon-Kwon Koo
Journal: Journal of the American College of Cardiology (2015)
TCT-203 Use of Percutaneous Assist Device Therapy in Ventricular Septal Defects in Postinfraction Cardiogenic Shock
Authors: Maan Malahfji, Emmanuel Nunez Centeno, Smita I. Negi, Mahmoud Mahfouz, Bassil Nassir, Igor Gregoric, Biswajit O. Kar, Pranav Loyalka
Journal: Journal of the American College of Cardiology (2015)
BCR-ABL Tyrosine Kinase Activity Modulates the Phosphorylation, Localization and Function of Interferon Regulatory Factor 5 (irf-5) in Chronic Myeloid Leukemia (CML) Cells.
Authors: Michele Massimino, Livia Manzella, Fabio Stagno, Maria Letizia Consoli, Manuela Fallica, Alessandra Aloisi, Francesco Di Raimondo, Angelo Messina, Paolo Vigneri
Journal: Blood (2009)
Case 37-1976
Authors: Richard C. Cabot, Robert E. Scully, James J. Galdabini, Betty U. McNeely, Rudolf Toch, Stanley J. Robboy
Journal: New England Journal of Medicine (1976)

Presentation of CaseA four-day-old girl was admitted to the hospital because of leukemia.She was born at 38 weeks' gestation of the third pregnancy of a healthy mother aged 28 years. The pregnancy was complicated at six weeks by an untreated nonspecific viral-like illness and one month before delivery by external otitis, which was treated with aspirin, acetaminophen and local drops. Two weeks before delivery hypertension was noted, and hydrochlorothiazide was prescribed. The onset of labor was spontaneous, and delivery occurred within three hours. The birth weight was 3275 g. The child had a "blueberry-muffin" appearance, with numerous purple . . .
TCT-467 Results of Longest Available Clinical Follow-up of a Cohort of “Real-World” Patients Treated Exclusively with Drug-Eluting Stents: the DESIRE (Drug-Eluting Stents In the REal world) Registry
Authors: José de Ribamar Costa, Amanda Sousa, Ricardo A. Costa, Adriana Moreira, Lucas P. Damiani, J. Eduardo Sousa
Journal: Journal of the American College of Cardiology (2015)
A Nationwide Observational Study of the Israeli Experience with Ponatinib Outside Clinical Trials in Chronic Myeloid Leukemia
Authors: Adi Shacham Abulafia, Pia Raanani, David Lavie, Yulia Volchek, Ron Ram, Ilana Hellmann, Liat Shargian, Anna Gourevietch, Evgeni Chubar, Roy Ratzon, Uri Rozovski
Journal: Blood (2015)
Integrative network analysis of nineteen brain regions identifies molecular signatures and networks underlying selective regional vulnerability to Alzheimer’s disease
Authors: Minghui Wang, Panos Roussos, Andrew McKenzie, Xianxiao Zhou, Yuji Kajiwara, Kristen J. Brennand, Gabriele C. De Luca, John F. Crary, Patrizia Casaccia, Joseph D. Buxbaum, Michelle Ehrlich, Sam Gandy, Alison Goate, Pavel Katsel, Eric Schadt, Vahram Haroutunian, Bin Zhang
Journal: Genome Medicine (2016)

Alzheimer's disease (AD) is the most common form of dementia, characterized by progressive cognitive impairment and neurodegeneration. However, despite extensive clinical and genomic studies, the molecular basis of AD development and progression remains elusive. To elucidate molecular systems associated with AD, we developed a large scale gene expression dataset from 1053 postmortem brain samples across 19 cortical regions of 125 individuals with a severity spectrum of dementia and neuropathology of AD. We excluded brain specimens that evidenced neuropathology other than that characteristic of AD. For the first time, we performed a pan-cortical brain region genomic analysis, characterizing the gene expression changes associated with a measure of dementia severity and multiple measures of the severity of neuropathological lesions associated with AD (neuritic plaques and neurofibrillary tangles) and constructing region-specific co-expression networks. We rank-ordered 44,692 gene probesets, 1558 co-expressed gene modules and 19 brain regions based upon their association with the disease traits. The neurobiological pathways identified through these analyses included actin cytoskeleton, axon guidance, and nervous system development. Using public human brain single-cell RNA-sequencing data, we computed brain cell type-specific marker genes for human and determined that many of the abnormally expressed gene signatures and network modules were specific to oligodendrocytes, astrocytes, and neurons. Analysis based on disease severity suggested that: many of the gene expression changes, including those of oligodendrocytes, occurred early in the progression of disease, making them potential translational/treatment development targets and unlikely to be mere bystander result of degeneration; several modules were closely linked to cognitive compromise with lesser association with traditional measures of neuropathology. The brain regional analyses identified temporal lobe gyri as sites associated with the greatest and earliest gene expression abnormalities. This transcriptomic network analysis of 19 brain regions provides a comprehensive assessment of the critical molecular pathways associated with AD pathology and offers new insights into molecular mechanisms underlying selective regional vulnerability to AD at different stages of the progression of cognitive compromise and development of the canonical neuropathological lesions of AD.
The Recently Suggested MDS/MPN Subgroup “Refractory Anemia with Ring Sideroblasts Associated with Marked Thrombocytosis (RARS-T)” Demonstrates Unique Clinical, Cytogenetic, and Molecular Aspects: A Comprehensive Analysis of 57 Cases Strictly Defined According to WHO Criteria
Authors: Ulrike Bacher, Johanna Flach, Claudia Haferlach, Tamara Alpermann, Wolfgang Kern, Susanne Schnittger, Torsten Haferlach
Journal: Blood (2010)
TCT-679 The third generation Edwards Novaflex/SAPIEN 3 TAVR device: Impact of sizing guidelines for transfemoral access suitability and shortterm results
Authors: Marie-Isabel K. Murray, Nicolas A. Geis, Sven T. Pleger, Klaus Kallenbach, Hugo A. Katus, Raffi Bekeredjian, Emmanuel Chorianopoulos
Journal: Journal of the American College of Cardiology (2015)
TCT-741 Atrial Septal Occlusion: Atrial Disks' Deformation Is Independent Of Waist Deformation
Authors: Manolis Vavuranakis, Dimitrios A. Vrachatis, Angelos-Michail Kolokathis, Konstantinos Kalogeras, Theodoros Papaioannou, Maria Lavda, Evangelia Bei, Maria Kariori, Carmen Moldovan, Sophia Vaina, Euaggelos Oikonomou, Gerasimos Siasos, Dimitrios Tousoulis
Journal: Journal of the American College of Cardiology (2015)
Brentuximab Vedotin with RCHOP As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL): Results from an Ongoing Phase 2 Study
Authors: Christopher A. Yasenchak, Ahmad Halwani, Ranjana Advani, Stephen Ansell, Lihua Elizabeth Budde, John M. Burke, Charles M. Farber, Beata Holkova, Luis E. Fayad, Kathryn S. Kolibaba, Mark Knapp, Martha Li, Thomas J. Manley, Dipti Patel-Donnelly, Mahesh Seetharam, Habte A. Yimer, Nancy L Bartlett
Journal: Blood (2015)
Announcing a New <i>JAMA Internal Medicine</i> Website
Authors: James A. Colbert, Robert Steinbrook, Rita F. Redberg
Journal: JAMA Internal Medicine (2016)

We at JAMA Internal Medicine are excited to announce a newly redesigned website to coincide with the launch of a new online JAMA Network platform (http://www.jamanetwork.com/journals/jamainternalmedicine). Key features of this new site include the following:
Comparison of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), Modification of Diet in Renal Disease (MDRD) Study Equations and A Formula Based on Cystatin-C and Serum Creatinine for the Estimation of Glomerular Filtration Rate in Patients with Multiple Myeloma; Is It Time to Change From MDRD to CKD-EPI Equation?
Authors: Meletios Athanasios Dimopoulos, Efstathios Kastritis, Eirini Katodritou, Anastasia Pouli, Eurydiki Michalis, Dimitrios Christoulas, Maria Gkotzamanidou, Ioannis Papassotiriou, Konstantinos Zervas, Evangelos Terpos
Journal: Blood (2011)
Orally Active Inhibitors of the Imatinib Resistant Bcr-Abl Mutant T315I.
Authors: William C. Shakespeare, Frank Wang, Qihong Xu, Xiaotian Zhu, Narayana Narasimham, Chester A. Metcalf, Yihan Wang, Raji Sundaramoorthi, Wei-Sheng Huang, Dong Zou, Mathew Thomas, Jan Romero, David Wen, Ingrid Chen, Lisi Cai, Shuangying Liu, Scott Wardwell, Yaoyu Ning, Jeff Keats, Joseph Snodgrass, Karin Russian, Marc Broudy, Thomas O’Hare, Caitlyn Smith, Amie Corbin, Brian Druker, John Iuliucci, David Dalgarno, Tomi K. Sawyer, Tim Clackson
Journal: Blood (2006)
Cardiotoxicity and Treatment Efficacy of Not Pegilated Liposomal Doxorubicin in Haematological Malignancies: Our Experience.
Authors: Alfredo Gagliardi, Maria Lucia Boffa, Gaetana Capobianco, Concetta Cotarelli, Donatella De Blasi, Lucia Liguori, Ruggiero Orlando, Angiola Rocino, Maria Maddalena Spiezia, Luigi Ziello, Eustachio Miraglia
Journal: Blood (2007)
Utility of single vs tandem autotransplants for advanced testes/germ cell cancer: An Autologous Blood and Marrow Transplant Registry (ABMTR) analysis
Authors: P. J. Stiff, H. M. Lazarus, R. W. Childs, W. Perez, J. Carreras, J. Klein, D. J. Rizzo
Journal: Journal of Clinical Oncology (2004)

4536 Background: While tandem autografts are commonnly used to treat pts with advanced testes cancer, their value vs a single transplant is unknown. Methods: We performed a retrospective cohort analysis of all cases with detailed research data reported to the ABMTR between 1989–2001. Outcomes were analyzed by the actual number of transplants performed and by “intent to treat” for single vs tandem trasnplants. To remove waiting time bias for second transplant, calculations were based on pts alive at 4.3 mos, the longest time between 1st and planned 2nd transplant. Results: A total of 303 pts were reported; 259 were analyzed. Their median age was 32; median time from diagnosis to first transplant was 13 mos and median f/u of survivors was 62 months. Of the 259, 165(64%) underwent one planned transplant, 81 (31%) tandem transplants and 13(5%) underwent only one of two planned transplants. Of pts with non-seminoma, 19, 14 and 33% were in the good, intermediate and poor risk International Prognostic Score groups. First remission transplants were done in 14%, and 41, 20, and 14% were after 1, 2 or 3 salvage attempts. Prior to first transplant 20% were NED, 6% marker positive only, and 74% had measurable disease. Treatment related mortality was 2% at 1 year, while the PFS was 51, and 39% at 1 and 5 years, and the survival (OS) was 72 and 34% respectively. Recurrent cancer was the cause of death in 93%. The groups were balanced for performance status, risk group and seminoma histology. Those receiving one transplant were more likely to be platinum sensitive and to have received more than 2 prior regimens. In univariate analysis, the PFS for pts undergoing one vs both planned transplants was 43 and 34% at 1 and 5 years, and the 5 yr OS were 47 and 35% respectively. For the “intent to treat” analyses, those receiving one planned vs one or both planned tandem transplants, the PFS was 43 and 32% at 5 years, and the 5 yr OS was 47 and 33% respectively. The differences were not statistically different. Conclusions: Tandem transplants appear not to offer significant advantages compared to a single transplant. A prospective randomized trial is warranted. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bristol-Myers Squibb provided a research grant to the American Bone Marrow Transplant Registry for this study
Afraid That I’ll Not Be Afraid—A Paradox of Care
Authors: Chiara Catania
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
TCT-457 Assessment of Optimal Drug-Eluting Stent Expansion to prevent target lesion revascularization with OCT guidance.
Authors: Yoshinori Sanuki, Shinjo Sonoda, Hironori Takami, Yoshitaka Muraoka, Yuki Tsuda, Masaru Araki, Yutaka Otsuji
Journal: Journal of the American College of Cardiology (2015)
GW27-e0327 An unusual echocardiographic performance of impaired left ventricular diastolic function in systolic heart failure patients: normal ratios of both mitral E/A and annulus e'/a'
Authors: Wenjing Zhang, Yali Yang, Xinfang Wang, Qing LV, Jing Wang, Li Zhang, Jinfeng Liu, Mingxing Xie
Journal: Journal of the American College of Cardiology (2016)
A Multicenter Comparison of Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation with Tandem Autologous Stem Cell Transplantation in Multiple Myeloma.
Authors: Chang-Ki Min, Hwak Kim, Kihyun Kim, Jae-Yong Kwak, Seung Tae Lee, Jong Ho Won, Sung-Soo Yoon, Jae Hoon Lee, Cheol Won Suh
Journal: Blood (2007)
TCT-785 Comparison of hybrid endovascular and open surgical repair for proximal aortic arch diseases
Authors: Woong Chol Kang, Jeonggeun Moon, Taehoon Ahn, Donghoon Choi, Wook-Jin Chung, Sihun Kim, Myeong Gun Kim, Do Yun Lee, Pyung Chun Oh, Chul-Hyun Park, Eak Kyun Shin, Young Nam Youn, Young-Guk Ko
Journal: Journal of the American College of Cardiology (2015)
HEMODYNAMIC ASSESSMENT OF LOW FLOW, LOW GRADIENT SEVERE AORTIC STENOSIS WITH PRESERVED EF USING A PRESSURE WIRE
Authors: Zaher Fanari, Prasad Gunasekaran, Arslan Shaukat, Jhapat Thapa, Kamleish Persad, Sumaya Hammami, Joseph West, Mark Wiley, Buddhadeb Dawn, William Weintraub, Peter Tadros, Andrew J. Doorey
Journal: Journal of the American College of Cardiology (2017)
SOX2 Is the Determining Oncogenic Switch in Promoting Lung Squamous Cell Carcinoma from Different Cells of Origin
Authors: Giustina Ferone, Ji-Ying Song, Kate D. Sutherland, Rajith Bhaskaran, Kim Monkhorst, Jan-Paul Lambooij, Natalie Proost, Gaetano Gargiulo, Anton Berns
Journal: Cancer Cell (2016)

Lung squamous cell carcinoma (LSCC) is a devastating malignancy with no effective treatments, due to its complex genomic profile. Therefore, preclinical models mimicking its salient features are urgently needed. Here we describe mouse models bearing various combinations of genetic lesions predominantly found in human LSCC. We show that SOX2 but not FGFR1 overexpression in tracheobronchial basal cells combined with Cdkn2ab and Pten loss results in LSCC closely resembling the human counterpart. Interestingly, Sox2;Pten;Cdkn2ab mice develop LSCC with a more peripheral location when Club or Alveolar type 2 (AT2) cells are targeted. Our model highlights the essential role of SOX2 in commanding the squamous cell fate from different cells of origin and represents an invaluable tool for developing better intervention strategies.
TCT-452 Four-Year Clinical and Angiographic Outcomes of Percutaneous Coronary Intervention with Everolimus-Eluting Stents for the Treatment of Cardiac Allograft Vasculopathy
Authors: Christopher T. Vanichsarn, Boris Arbit, Richard Cheng, Tamar Aintablian, Raj Makkar, Jon Kobashigawa, Babak Azarbal
Journal: Journal of the American College of Cardiology (2015)
Rapid Loss of Membrane Integrity and Irreversible Commitment to Cell Death of Primary AML Stem Cells: A Novel Activity for 4-benzyl, 2-methyl,1,2,4-Thiadiazolidine,3,5 Dione (TDZD-8).
Authors: Monica L. Guzman, Xiaojie Li, Cheryl Corbett, Randall M. Rossi, Timothy Bushnell, Craig T. Jordan
Journal: Blood (2006)
GW27-e1069 Synergistic effect of a tissue kallikrein 1 and tissue inhibitor of matrix metalloproteinase 1 co expression vector on the proliferation of rat vascular smooth muscle cells
Authors: Gao Jie, Huizhen Yu, Shujie Huang, Hong Xiang, Feng Li, Weiping Zheng, Pengli Zhu
Journal: Journal of the American College of Cardiology (2016)
Phase II trial of oxaliplatin and gemcitabine in patients with malignant pleural or peritoneal mesothelioma
Authors: M. S. Boyar, M. Hesdorffer, R. N. Taub
Journal: Journal of Clinical Oncology (2006)

17133 Background: A prior phase II trial of oxaliplatin and gemcitabine in malignant pleural mesothelioma reported activity with a 40% partial response rate and stable disease in 24% of 25 previously untreated patients (Schutte W. et al., Clin Lung Cancer 2003;4:294). This trial was designed to further evaluate the efficacy of oxaliplatin and gemcitabine in patients with malignant pleural or peritoneal mesothelioma. Methods: Patients with histologically-confirmed malignant pleural or peritoneal mesothelioma not amenable to curative surgical treatment are eligible for enrollment on this single-institution phase II trial. One prior chemotherapy regimen is allowed, including pemetrexed with a platinum compound or gemcitabine. Presence of at least one radiologically-measurable lesion that has not been previously irradiated is required. Gemcitabine 1000 mg/m 2 IV over 90 minutes is administered followed by oxaliplatin 100 mg/m 2 IV over 2 hours on day 1 of a 14-day cycle. Treatment is continued for at least 6 cycles unless unacceptable toxicity or disease progression occurs. The primary outcome is to evaluate efficacy as measured by tumor response rate. The sequential two-stage design allows for enrollment of a total of 29 patients if 3 of 18 patients enrolled in the first stage have at least a partial response. Results: Ten eligible patients have been enrolled thus far and 6 are evaluable for response. Sites of disease include pleural (3) and peritoneal (3), and histologic subtypes are epithelioid (5) and sarcomatoid (1). Four patients had received prior chemotherapy. A total of 42 cycles have been given with a median of 8 cycles per patient. There are no partial or complete responses. Four patients have had stable disease for at least 4 months. Two patients with stable disease had received prior pemetrexed/gemcitabine or pemetrexed/cisplatin. Frequently observed toxicities include grade II fatigue, neuropathy and upper gastrointestinal dysmotility. Conclusion: This regimen of gemcitabine and oxaliplatin may provide disease stabilization in a subset of patients with malignant pleural and peritoneal mesothelioma, including those who have received prior chemotherapy. The regimen is well-tolerated. This study remains open to accrual. No significant financial relationships to disclose.
The Combination of the Novel Syk Inhibitor TAK659 with Decitabine Exerts Synergistic Cytotoxic Effects Against FLT3/ITD Mutated Acute Myeloid Leukemia Cells
Authors: Edwin Stage, Magdalena Czader, Heather O'Leary, H. Scott Boswell, Larry D. Cripe, Hamid Sayar, Cedric Dos Santos, Mark J. Levis, Heiko Konig
Journal: Blood (2015)
Tolerance Induction To FIX Padua With AAV Liver Gene Transfer In Inhibitor-Prone Hemophilia B Dogs
Authors: Julie M Crudele, Jonathan D Finn, Nicholas B Martin, Joshua I Siner, Yifeng Chen, Shangzhen Zhou, Glenn Niemeyer, Clinton D. Lothrop, Federico Mingozzi, Katherine A. High, Valder R. Arruda
Journal: Blood (2013)